3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hematologic Diseases
1
Granulosa Cell Tumor
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
48
fludarabine phosphate
36
Methotrexate
26
Cytarabine
24
fludarabine
23
Whole-Body Irradiation
23
Rituximab
19
Cyclosporine
19
Antilymphocyte Serum
18
Peripheral Blood Stem Cell Transplantation
17
Filgrastim
17
Busulfan
17
Mycophenolic Acid
16
Tacrolimus
15
Azacitidine
15
Alemtuzumab
15
Radiotherapy
13
Melphalan
13
Imatinib Mesylate
13
Etoposide
13
Vincristine
11
Methylprednisolone
11
Cord Blood Stem Cell Transplantation
11
Dexamethasone
10
venetoclax
8
Granulocyte Colony-Stimulating Factor
8
Clofarabine
8
thymoglobulin
7
sargramostim
7
nilotinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts